Hypertension nursing: assessment, interventions, and pharmacology reference

Hypertension affects nearly half of US adults and is the leading modifiable risk factor for cardiovascular disease, stroke, and chronic kidney disease. Most patients are asymptomatic for years while cumulative vascular damage accrues — a pattern that makes hypertension simultaneously common and dangerous in every clinical setting. Nurses encounter hypertension on every unit: as a primary admission diagnosis, a comorbidity complicating surgical recovery, a trigger for acute decompensation in heart failure, and as a standalone emergency when BP exceeds crisis thresholds. Understanding hypertension — its classification systems, hemodynamic mechanisms, antihypertensive pharmacology, and crisis management — is foundational for NCLEX preparation and clinical practice.

Key facts at a glance

This reference covers ACC/AHA 2017 and JNC 8 classification, pathophysiology of primary and secondary hypertension, nursing assessment, antihypertensive pharmacology, hypertensive crisis management, and NCLEX-style practice questions. Pair it with the heart failure nursing reference for managing hypertension-driven decompensation, the stroke nursing reference for hypertension-related cerebrovascular emergencies, and the nursing lab values cheat sheet for interpreting the renal and electrolyte panels essential in antihypertensive monitoring.

Classification and staging: ACC/AHA 2017 vs JNC 8

Two classification systems are currently in use in nursing education, and knowing both is essential for NCLEX and clinical practice. The ACC/AHA 2017 guidelines (Whelton et al.) lowered the definition of hypertension to 130/80 mmHg — a change that approximately doubled the number of Americans classified as hypertensive but kept pharmacotherapy thresholds similar to prior guidelines. JNC 8 (James et al., 2014) remains widely cited in nursing curricula and sets the pharmacotherapy threshold at 140/90 for most adults.

Key teaching point for NCLEX: The distinction between urgency and emergency is not determined by the BP number alone. Both involve SBP ≥180 or DBP ≥120. The emergency is defined by the presence of acute target organ damage — new neurological deficits, chest pain/ST changes, pulmonary edema, oliguria, or visual changes. A patient with BP 210/120 and no organ damage has a hypertensive urgency. A patient with BP 180/110 and new-onset confusion has a hypertensive emergency.

JNC 8 note: JNC 8 raised the pharmacotherapy threshold for adults ≥60 years to SBP ≥150 mmHg (or DBP ≥90), reflecting evidence that aggressive treatment in this population offered limited additional benefit over a 150 mmHg target. ACC/AHA 2017 does not make this age-based distinction and targets <130/80 for most adults including older patients. Both frameworks appear in NCLEX questions — recognize the difference when reading clinical scenarios.

Pathophysiology

Primary hypertension: the multifactorial model

Primary (essential) hypertension accounts for 90–95% of all cases. No single cause is identified; instead, blood pressure becomes persistently elevated through a convergence of genetic predisposition, environmental factors, and maladaptive physiologic responses. Blood pressure is the product of cardiac output (CO) and systemic vascular resistance (SVR): BP = CO × SVR. Sustained hypertension requires sustained elevation in one or both of these variables.

In early hypertension, cardiac output is often mildly elevated — driven by increased sympathetic tone, sodium and water retention, and elevated heart rate. Over time, as the body attempts to normalize flow, peripheral vascular resistance rises: arteriolar smooth muscle hypertrophies, endothelial dysfunction reduces nitric oxide-mediated vasodilation, and structural arterial changes permanently raise SVR. At this stage, even if CO normalizes, SVR maintains the elevated BP. This explains why established hypertension is primarily an SVR-mediated disease and why vasodilating drugs (ACE inhibitors, CCBs) are so effective.

The renin-angiotensin-aldosterone system (RAAS)

The RAAS is the central hormonal axis of blood pressure regulation and a primary target of antihypertensive pharmacotherapy. When renal perfusion pressure falls — or when the macula densa senses reduced sodium delivery — juxtaglomerular cells in the kidney secrete renin. Renin cleaves angiotensinogen (from the liver) to angiotensin I. Angiotensin-converting enzyme (ACE), primarily in the pulmonary vasculature, cleaves angiotensin I to angiotensin II — the effector molecule of the RAAS.

Angiotensin II exerts four major hypertensive effects:

1. Direct vasoconstriction — acts on vascular smooth muscle AT₁ receptors, raising SVR
2. Aldosterone release — from the adrenal cortex, promoting sodium and water retention, expanding intravascular volume
3. ADH release — from the posterior pituitary, increasing free water reabsorption in the collecting duct
4. Sympathetic potentiation — facilitates norepinephrine release at sympathetic nerve terminals

Chronic RAAS activation in hypertension drives both volume expansion and vasoconstriction simultaneously — explaining why both diuretics and RAAS-blocking drugs are effective antihypertensives and why combination therapy is often required.

Secondary hypertension: identifiable causes

Secondary hypertension (5–10% of cases) has a specific underlying etiology. Identifying and treating the cause can be curative. The most clinically important causes are:

• Primary aldosteronism — aldosterone-producing adenoma or bilateral adrenal hyperplasia causes sodium retention, hypokalemia, and suppressed renin. Screen with aldosterone-to-renin ratio if hypertension is resistant to treatment or associated with hypokalemia.
• Renal artery stenosis — reduced renal perfusion activates RAAS. Clue: new or worsening hypertension in a patient under 35 (fibromuscular dysplasia) or older patient with atherosclerosis; bruits over renal arteries.
• Renovascular/parenchymal disease — CKD itself elevates BP via volume expansion and RAAS activation; conversely, hypertension accelerates CKD.
• Obstructive sleep apnea — intermittent hypoxia drives sympathetic activation and RAAS upregulation; consider in obese patients with resistant hypertension.
• Medication-induced — NSAIDs (inhibit prostaglandin-mediated vasodilation), oral contraceptives, decongestants (pseudoephedrine), stimulants, corticosteroids, and some immunosuppressants.
• Pheochromocytoma — catecholamine-secreting tumor; classic triad of episodic headache, sweating, and palpitations with paroxysmal hypertension.
• Hypothyroidism / hyperthyroidism — both can elevate BP via different hemodynamic mechanisms.

End-organ damage mechanisms

Sustained hypertension damages target organs through two primary mechanisms: mechanical stress on vascular walls and accelerated atherosclerosis from endothelial injury.

• Brain: Cerebral arterioles hypertrophy and lose autoregulatory capacity. Lacunar infarcts develop from small vessel disease. Hypertensive encephalopathy results when BP exceeds the upper limit of cerebral autoregulation (~180 mmHg MAP), causing cerebral edema and dysfunction.
• Heart: Chronic pressure overload causes left ventricular hypertrophy (LVH) — a compensatory adaptation that becomes maladaptive. LVH reduces ventricular compliance, impairing diastolic filling (heart failure with preserved EF, HFpEF). Coronary artery disease accelerates. Eventually, systolic dysfunction may develop.
• Kidneys: Hypertensive nephrosclerosis — glomerular hypertension injures podocytes and the filtration barrier, causing proteinuria and progressive glomerulosclerosis. Hypertension is the second leading cause of ESRD in the US after diabetes.
• Eyes: Hypertensive retinopathy progresses from arteriolar narrowing (grade 1) to AV nicking (grade 2) to flame hemorrhages and cotton wool spots (grade 3) to papilledema (grade 4, indicating hypertensive emergency).
• Aorta: Sustained hypertension weakens the aortic wall, creating conditions for aneurysm formation and aortic dissection.

Clinical presentation and assessment

Usually asymptomatic until complications develop

Hypertension earns its label as “the silent killer” because most patients have no symptoms at normal-to-moderate BP elevations. The absence of symptoms does not indicate absence of end-organ damage; atherosclerosis and LVH may progress silently for years. When symptoms do occur at elevated BP, they often reflect complications rather than hypertension itself:

• Headache — common complaint attributed to hypertension, though evidence linking uncomplicated hypertension to headache is inconsistent. An occipital headache that is worst on waking may suggest hypertensive urgency.
• Visual changes — blurring, floaters, or visual loss suggest hypertensive retinopathy or retinal artery/vein occlusion.
• Chest pain, dyspnea — suggest hypertension-precipitated cardiac complications (ACS, acute HF).
• Neurological changes — confusion, focal deficits, or altered LOC in a hypertensive patient require immediate evaluation for hypertensive encephalopathy or stroke.
• Epistaxis — frequently associated with elevated BP; though correlation is debated, patients with severe hypertension presenting with nosebleed warrant BP measurement and management.

Blood pressure measurement technique

Accurate BP measurement is a core nursing skill. Errors in technique systematically mis-classify patients. Correct technique per ACC/AHA 2017 guidance:

1. Patient seated quietly for ≥5 minutes before measurement; back supported, feet flat on the floor
2. No caffeine, smoking, or exercise in the prior 30 minutes
3. Bladder emptied before measurement
4. Arm bared, at heart level (supported on a surface — not held up by patient or nurse)
5. Cuff bladder encircles 80% of arm circumference; correct sizing is mandatory (too small → falsely elevated reading)
6. Palpate brachial artery, place stethoscope bell over it
7. Inflate cuff 20–30 mmHg above disappearance of radial pulse
8. Deflate at 2 mmHg/second; record Korotkoff I (first sound = SBP) and Korotkoff V (disappearance = DBP)
9. Average 2 readings ≥1 minute apart; a third reading if first two differ by >10 mmHg
10. Measure in both arms on initial evaluation — a difference >10 mmHg SBP between arms warrants further evaluation (possible subclavian stenosis or vascular disease)

White-coat hypertension (elevated in office, normal at home) occurs in 15–30% of patients and can be identified via ambulatory blood pressure monitoring (ABPM) or home BP monitoring. Masked hypertension (normal in office, elevated at home) is less common but associated with increased cardiovascular risk.

Orthostatic blood pressure assessment

Orthostatic hypotension — a drop in SBP ≥20 mmHg or DBP ≥10 mmHg within 3 minutes of standing — is relevant in hypertensive patients for several reasons: antihypertensive medications (especially diuretics, alpha-blockers, and vasodilators) cause orthostasis; elderly patients are at fall risk; and overtreatment of hypertension in older adults can cause symptomatic hypotension.

Technique: measure BP supine after 5 minutes, then standing at 1 and 3 minutes. Document symptoms (lightheadedness, near-syncope) at each position.

Diagnostic criteria and workup

Hypertension is diagnosed when BP is elevated on ≥2 separate occasions on ≥2 separate visits (ACC/AHA 2017), or when ambulatory monitoring confirms sustained elevation. A single elevated reading in an acute care setting is not sufficient for a new diagnosis — it may reflect white-coat effect, pain, anxiety, or acute illness.

Initial workup for new hypertension diagnosis:

• Complete metabolic panel (BMP/CMP): Assess renal function (creatinine, BUN, eGFR), electrolytes (hypokalemia suggests primary aldosteronism or thiazide effect), glucose (diabetes as comorbidity). See the nursing lab values cheat sheet for reference ranges.
• Urinalysis with microscopy: Proteinuria or hematuria suggests hypertensive nephropathy or glomerulonephritis as a secondary cause.
• Fasting lipid panel: Assess 10-year ASCVD risk (which informs pharmacotherapy decisions under ACC/AHA guidelines).
• Fasting glucose or HbA1c: Diabetes and metabolic syndrome frequently co-occur with hypertension.
• 12-lead EKG: Screen for LVH (voltage criteria: Sokolow-Lyon, Cornell), left atrial enlargement, existing ischemic changes.
• Thyroid-stimulating hormone (TSH): Rule out thyroid dysfunction as a secondary cause.
• Uric acid: Gout comorbidity affects drug selection (thiazides raise uric acid; losartan is uricosuric).

Secondary hypertension screening (when to order):

• Hypertension onset before age 30 with no family history
• Resistant hypertension (BP uncontrolled on 3 drugs including a diuretic at maximum doses)
• Hypokalemia without diuretic use
• Episodic hypertension with headache, sweating, or palpitations (pheochromocytoma workup)
• Abdominal bruit or asymmetric renal sizes on imaging (renal artery stenosis)
• Abrupt worsening of previously controlled hypertension

Nursing interventions

Nursing management of the hypertensive patient spans assessment, monitoring, medication administration, safety, and patient education. The table below organizes key nursing actions by system or priority.

Lifestyle modification: expected BP reductions

When counseling patients, quantifying the expected benefit of each lifestyle change helps motivate adherence. Evidence-based estimates per ACC/AHA 2017:

• DASH diet: SBP reduction of 8–14 mmHg
• Sodium restriction to <1.5 g/day: 5–6 mmHg
• Weight loss (1 mmHg per kg lost): up to 5 mmHg with 5 kg loss
• Aerobic exercise 90–150 min/week: 5–8 mmHg
• Alcohol moderation (≤1 drink/day women, ≤2 men): 3–4 mmHg

For patients with Stage 1 hypertension and low ASCVD risk (<10% 10-year risk), lifestyle modification alone is the initial management strategy — a 3–6 month trial before reassessing the need for pharmacotherapy.

Antihypertensive pharmacology

Five major drug classes form the foundation of antihypertensive therapy. The table below covers each class with mechanism, prototype drug, key nursing considerations, and adverse effects to monitor. These drugs appear extensively on NCLEX — knowing hold parameters, monitoring requirements, and patient education for each class is essential.

Compelling indications: matching drug class to patient profile

ACC/AHA guidelines recommend specific antihypertensive classes based on patient comorbidities — a concept tested heavily on NCLEX:

• Post-MI / coronary artery disease: Beta-blocker + ACE inhibitor (reduce cardiac remodeling, mortality benefit)
• Heart failure with reduced EF (HFrEF): Beta-blocker + ACE inhibitor or ARB + loop diuretic ± aldosterone antagonist (spironolactone) — avoid non-DHP CCBs
• Diabetes + hypertension: ACE inhibitor or ARB (nephroprotective — reduce proteinuria)
• CKD with proteinuria: ACE inhibitor or ARB (first-line — slow progression regardless of diabetes status)
• Pregnancy: Methyldopa (preferred), labetalol, nifedipine — ACE inhibitors and ARBs are contraindicated in pregnancy
• Isolated systolic hypertension in elderly: Thiazide diuretics or DHP CCBs
• Hypertension + BPH: Alpha-1 blocker (treats both conditions)
• Hypertension + migraine: Beta-blocker or verapamil (migraine prophylaxis benefit)

Hypertensive crisis: urgency vs emergency

Defining the distinction

Hypertensive crisis is the term for severely elevated blood pressure (SBP ≥180 or DBP ≥120 mmHg) that requires intervention. The critical bifurcation is whether acute target organ damage is present — this, not the blood pressure number, determines urgency vs emergency and drives the management approach.

Hypertensive urgency:

• SBP ≥180 or DBP ≥120 mmHg
• No evidence of acute target organ damage
• Patient may be asymptomatic or have headache
• Management: oral antihypertensives (restart missed doses or intensify outpatient regimen), BP reduction over hours to days, no requirement for ICU or IV therapy

Hypertensive emergency:

• SBP ≥180 or DBP ≥120 mmHg
• WITH evidence of acute target organ damage — any of the following:
  • Neurological: hypertensive encephalopathy (confusion, seizures), acute ischemic stroke, hemorrhagic stroke
  • Cardiac: acute myocardial infarction, unstable angina, acute decompensated heart failure with pulmonary edema
  • Renal: acute hypertensive nephrosclerosis (rising creatinine, hematuria, proteinuria)
  • Vascular: aortic dissection, malignant hypertension with microangiopathic hemolytic anemia
  • Ocular: grade III–IV hypertensive retinopathy (hemorrhages, papilledema)
• Management: ICU admission, IV antihypertensives, arterial line BP monitoring, controlled BP reduction

Why controlled reduction matters: the autoregulation principle

Paradoxically, rapidly lowering BP in a hypertensive emergency can worsen outcomes. Patients with chronic hypertension have reset their cerebral, coronary, and renal autoregulatory curves upward. The lower end of autoregulation is approximately MAP 120–150 mmHg in a chronically hypertensive patient (vs. ~70 mmHg in normotensive patients). If MAP is reduced to “normal” (70–80 mmHg) too rapidly, perfusion to these organs falls below autoregulatory capacity — causing watershed infarcts, cerebral ischemia, and worsening acute kidney injury.

Target for most hypertensive emergencies: Reduce MAP by no more than 25% in the first hour, then target BP ~160/100 mmHg over the next 2–6 hours, then gradual normalization over 24–48 hours. The exception is aortic dissection — aggressive BP reduction (target SBP <120 mmHg) within minutes is lifesaving.

IV antihypertensives for emergency management

Nursing priorities in hypertensive emergency

1. Establish IV access — large-bore peripheral or central line; IV antihypertensives require reliable access
2. Continuous BP monitoring — arterial line if available for beat-to-beat monitoring; non-invasive cycling every 5 minutes at minimum
3. Neurological assessment every 15–30 minutes — mental status, pupils, focal deficits, GCS; deterioration may indicate worsening hypertensive encephalopathy or hemorrhagic stroke
4. 12-lead EKG — rule out concurrent ACS; ST changes may indicate demand ischemia from elevated afterload
5. Urine output monitoring — Foley catheter; oliguria suggests renal involvement or excessive BP reduction
6. Labs — BMP (creatinine, potassium), CBC (microangiopathic hemolytic anemia), troponin, BNP/NT-proBNP (if HF suspected), urinalysis
7. Ophthalmology or fundoscopic exam — papilledema confirms malignant hypertension
8. Titration documentation — document every BP reading, every dose adjustment, and patient response in real time
9. Patient and family communication — high anxiety is expected; brief, calm explanation of monitoring and treatment rationale reduces sympathetic activation

Hypertension in special populations

Pregnancy: Gestational hypertension (BP ≥140/90 after 20 weeks, no proteinuria) and pre-eclampsia (hypertension + proteinuria or end-organ features) require specialized management. Severe pre-eclampsia (SBP ≥160 or DBP ≥110) is a medical emergency requiring IV labetalol or hydralazine and IV magnesium sulfate for seizure prophylaxis. ACE inhibitors and ARBs are teratogenic and absolutely contraindicated at any point in pregnancy. Methyldopa and labetalol are preferred for chronic management; nifedipine XL is an alternative.

Older adults: Isolated systolic hypertension (ISH) — elevated SBP with normal DBP — is the predominant pattern in adults over 60, reflecting reduced arterial compliance with age. Treatment reduces stroke risk substantially. However, overly aggressive treatment increases fall risk; orthostatic hypotension must be monitored at every visit. A reasonable target of <130/80 (ACC/AHA) must be balanced against fall prevention in frail elderly patients.

NCLEX-style practice questions

Question 1

A nurse is preparing to administer lisinopril 10 mg to a patient with hypertension. The patient’s most recent labs show K⁺ 5.8 mEq/L, Na⁺ 139 mEq/L, and creatinine 1.1 mg/dL. What is the priority nursing action?

A) Administer the medication as ordered B) Hold the medication and notify the provider C) Administer the medication and increase IV fluid rate D) Check a repeat potassium level before making a decision

Correct answer: B

Rationale: ACE inhibitors reduce aldosterone secretion and can cause hyperkalemia by decreasing renal potassium excretion. A K⁺ of 5.8 mEq/L is significantly elevated (normal: 3.5–5.0 mEq/L) and exceeds the standard hold parameter of 5.5 mEq/L for ACE inhibitors. Administering lisinopril would risk worsening hyperkalemia, which can cause life-threatening cardiac arrhythmias. The priority is to hold the medication and notify the provider for guidance on dose adjustment, potassium-lowering measures, or drug substitution. Rechecking the lab without withholding the drug (option D) delays appropriate action and is not the standard of care. IV fluids do not correct hyperkalemia in this context.

Question 2

A patient presents to the emergency department with blood pressure 196/118 mmHg. The nurse performs an assessment. Which finding would indicate this is a hypertensive emergency rather than a hypertensive urgency?

A) The patient reports a throbbing occipital headache B) The patient has no regular antihypertensive medications C) The patient is confused and cannot follow commands D) The patient’s BP reading is higher than any prior documented reading

Correct answer: C

Rationale: The distinction between hypertensive urgency and emergency is the presence of acute target organ damage, not the BP level itself. Altered mental status (confusion, inability to follow commands) indicates neurological target organ involvement — either hypertensive encephalopathy or a cerebrovascular event — which classifies this as a hypertensive emergency requiring ICU admission and IV antihypertensives. Headache (option A) alone — while concerning — is a common nonspecific symptom that does not define emergency vs. urgency. Lack of medications (option B) may explain the elevated BP but does not classify severity. The absolute BP value or comparison to prior readings (option D) does not determine the urgency vs. emergency distinction.

Question 3

A patient who takes metoprolol succinate for hypertension is admitted for a procedure requiring NPO status. The patient’s morning BP is 142/86 mmHg and heart rate is 58 bpm. Which action should the nurse take?

A) Administer the metoprolol as scheduled B) Hold the metoprolol because the heart rate is below the hold parameter C) Hold the metoprolol because the patient is NPO D) Administer half the dose and document the adjustment

Correct answer: B

Rationale: The standard hold parameter for beta-blockers is HR <55–60 bpm (confirm with provider order) or SBP <90 mmHg. With a resting HR of 58 bpm, administering metoprolol risks further bradycardia, hypotension, and hemodynamic instability — particularly in a patient undergoing a procedure. The nurse should hold the medication and notify the provider. Being NPO (option C) is not the primary reason to hold a beta-blocker — most beta-blockers can be crushed and given via NG tube or held until the patient can take PO medications, but the HR parameter takes priority here. Administering half the dose (option D) is a medication error — nurses cannot alter prescribed doses without a provider order.

Question 4

A patient with a blood pressure of 188/114 mmHg is admitted to the ICU. The physician orders a nicardipine infusion with a target MAP reduction of 25% over the first hour. The patient’s current MAP is 139 mmHg. Which MAP would indicate the treatment target has been achieved?

A) 80 mmHg B) 100 mmHg C) 104 mmHg D) 115 mmHg

Correct answer: C

Rationale: The MAP target for hypertensive emergency is a reduction of no more than 25% in the first hour. 25% of 139 mmHg = approximately 35 mmHg. 139 − 35 = 104 mmHg. Reducing MAP to 80 mmHg (option A) or even 100 mmHg (option B) reduces MAP by more than 25%, risking cerebral, renal, and coronary ischemia in a patient whose autoregulatory curves are shifted upward by chronic hypertension. Option D (115 mmHg) represents only a ~17% reduction — acceptable but not at the 25% target. This calculation principle is high-yield for NCLEX critical care questions.

MAP formula: MAP = DBP + 1/3 (SBP − DBP). For BP 188/114: MAP = 114 + 1/3(74) = 114 + 25 = 139 mmHg.

Question 5

A patient recently started on hydrochlorothiazide for hypertension reports muscle cramping and weakness at a follow-up visit. Which laboratory finding would the nurse most expect?

A) K⁺ 5.9 mEq/L B) K⁺ 3.1 mEq/L C) Na⁺ 148 mEq/L D) Creatinine 3.2 mg/dL

Correct answer: B

Rationale: Thiazide diuretics inhibit sodium reabsorption in the distal convoluted tubule, increasing sodium delivery to the collecting duct and driving potassium excretion via aldosterone-mediated Na⁺/K⁺ exchange. The result is hypokalemia (K⁺ <3.5 mEq/L). Muscle cramping and weakness are classic symptoms of hypokalemia due to altered membrane excitability. Hyperkalemia (option A) occurs with ACE inhibitors and ARBs, not thiazides. Hypernatremia (option C) is not a typical thiazide effect — hyponatremia (particularly in elderly patients) is more common with thiazides due to free water retention. Elevated creatinine (option D) suggests renal failure, which is not the expected mechanism here.

Question 6

A patient taking clonidine for hypertension ran out of medication 2 days ago and has not been able to refill the prescription. The patient presents with BP 210/128 mmHg, heart rate 104 bpm, and reports severe anxiety and sweating. Which is the most likely cause of this presentation?

A) Worsening of underlying essential hypertension B) Development of a hypertensive emergency from end-organ damage C) Rebound hypertension from abrupt clonidine discontinuation D) Medication interaction from over-the-counter analgesics

Correct answer: C

Rationale: Abrupt discontinuation of clonidine causes rebound hypertension — a well-characterized withdrawal syndrome that typically occurs within 12–24 hours of stopping the drug. Clonidine is a central alpha-2 agonist that suppresses sympathetic outflow; abrupt cessation removes this suppression, resulting in a surge of norepinephrine and extreme sympathetic activation (hypertension, tachycardia, anxiety, diaphoresis). The treatment is to resume clonidine or substitute another antihypertensive while tapering. This is a critical patient education point: patients must never abruptly stop clonidine, and if a dose is missed, they should contact their provider immediately. The presentation is consistent with rebound rather than simply uncontrolled essential hypertension (option A, which would not typically present this acutely with sympathetic features) or primary end-organ damage (option B, which is a consequence, not a cause). OTC analgesics (option D) such as NSAIDs can raise BP but would not cause this acute presentation.

Internal links

This reference is part of the cardiovascular nursing series. Related topics:

• Atrial fibrillation nursing reference — rate vs rhythm control, anticoagulation, cardioversion
• Heart failure nursing reference — hypertension as the leading cause of HFpEF and HFrEF
• Stroke nursing reference — hypertension-related ischemic and hemorrhagic stroke
• EKG interpretation cheat sheet — identifying LVH criteria and hypertension-related rhythm changes
• Nursing lab values cheat sheet — K⁺, Na⁺, creatinine, and BMP interpretation for antihypertensive monitoring
• Nursing documentation guide — documenting BP trends, medication holds, and patient education
• Vital signs by age reference — normal BP ranges across pediatric and adult populations